Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2
The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | AKT1 | P31749 | 2/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | CDC25A | P30304 | 1/20 | 0.68 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | GMNN | O75496 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | PRKCG | P05129 | 1/20 | 0.49 |
| ▸ | PRKCB | P05771 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCH | P24723 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL28062058 | 0.84 | LPAR3 (0.58) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL11593283 | 0.84 | LMNA (0.81) | LMNAAKT1ESR1ADORA3CDC25A | |
| Cetrimonium SCHEMBL6377382 | 0.84 | LMNA (0.81) | LMNAAKT1ESR1ADORA3CDC25A | |
| Phosphoric Acid Monododecyl Ester SCHEMBL28718459 | 0.83 | LMNA (0.64) | LMNAAKT1ESR1ADORA3CDC25A | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL1272358 | 0.83 | LMNA (0.64) | LMNAAKT1ESR1ADORA3CDC25A | |
| Tetramethylammonium Ion SCHEMBL6553809 | 0.83 | AKT1 (0.67) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL9234856 | 0.82 | LMNA (0.96) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL8679882 | 0.82 | LMNA (0.67) | LMNAAKT1ESR1ADORA3CDC25A | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL1272360 | 0.82 | LMNA (0.62) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL28221734 | 0.82 | AKT1 (0.51) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551441-B2 | Water soluble silicon-containing granulate | BIO MINERALS NV (BE) | 2026-02-17 | — | — | US | claimed |
| US-20240408130-A1 | Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps | BIO MINERALS N.V. (BE) | 2024-12-12 | — | — | US | claimed |
| US-11878031-B2 | Silicic acids for use in the treatment of periodontitis | BIO MINERALS N.V. (BE) | 2024-01-23 | — | — | US | claimed |
| US-20220008454-A1 | Silicic Acids for Use in the Treatment of Periodontitis | BIO MINERALS N.V. (BE) | 2022-01-13 | — | — | US | claimed |
| CN-113226328-A | Silicic acid for treating periodontitis | 生物矿物股份有限公司 | 2021-08-06 | — | — | CN | claimed |
| WO-2020070300-A1 | SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS | BIO MINERALS N.V. (BE) | 2020-04-09 | — | — | WO | claimed |
| EP-3632449-A1 | SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS | Bio Minerals N.V. (BE) | 2020-04-08 | — | — | EP | claimed |
| US-12551441-B2 | Water soluble silicon-containing granulate | BIO MINERALS NV (BE) | 2026-02-17 | — | — | US | disclosed |
| US-20240408130-A1 | Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps | BIO MINERALS N.V. (BE) | 2024-12-12 | — | — | US | disclosed |
| US-11878031-B2 | Silicic acids for use in the treatment of periodontitis | BIO MINERALS N.V. (BE) | 2024-01-23 | — | — | US | disclosed |
| US-20220143078-A1 | Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps | BIO MINERALS N.V. (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220008454-A1 | Silicic Acids for Use in the Treatment of Periodontitis | BIO MINERALS N.V. (BE) | 2022-01-13 | — | — | US | disclosed |
| CN-113853202-A | Silicon-magnesium combination for preventing and treating muscle spasm | 生物矿物股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| EP-3650532-A1 | METHODS, APPARATUS AND KITS FOR BACTERIAL CELL LYSIS | Technische Universität Wien (AT) | 2020-05-13 | — | — | EP | disclosed |
| WO-2020070300-A1 | SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS | BIO MINERALS N.V. (BE) | 2020-04-09 | — | — | WO | disclosed |
| EP-3632449-A1 | SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS | Bio Minerals N.V. (BE) | 2020-04-08 | — | — | EP | disclosed |
| US-9289381-B2 | Stabilization and storage of biological pharmaceutical compositions | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2016-03-22 | — | — | US | disclosed |
| US-20130089912-A1 | METHODS AND COMPOSITIONS FOR THE STABILIZATION OF BIOLOGIC MATERIAL | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE | 2013-04-11 | — | — | US | disclosed |
| US-20120230944-A1 | STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-09-13 | — | — | US | disclosed |
| WO-2011069037-A2 | STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551441-B2 | Water soluble silicon-containing granulate | SI, GIPR, VIP | ADORA3 2072/4885LMNA 1265/4885AKT1 3666/4885 |
| US-20120230944-A1 | STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS | IL2, IL2RA, IL36G | ADORA3 4286/4885LMNA 2050/4885AKT1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.